THE LONG DAWN

Dispatches / Gene & cell

Rewriting the code of life

First plasmid DNA immunotherapy approved in the US, for a rare HPV airway disease

Small loops of DNA that teach the body to hunt a virus: a new kind of medicine enters the clinic.

ApprovedRegulator decision

What happened

  • The FDA granted accelerated approval on 30 Oct 2026 to Voceryq for adults with recurrent respiratory papillomatosis, wart-like airway growths caused by HPV types 6 and 11.
  • It delivers two DNA plasmids, one carrying HPV protein instructions and one an immune booster (IL‑12), into muscle cells using brief electrical pulses.
  • In an open-label trial of 32 adults, 7 of 26 people who had needed at least three prior surgeries needed none in the year after treatment.

What we don't know yet

  • Approval is based on fewer surgeries, an intermediate endpoint. Follow-up trials must confirm clinical benefit.
  • There was no control group in the trial described.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.